PIA
NTLA icon

Piedmont Investment Advisors’s Intellia Therapeutics NTLA Stock Holding History

Piedmont Investment Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-577
Closed -$16K – 1855
2018
Q2 		$16K Buy
+577
New +$14K ﹤0.01% 1656

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Piedmont Investment Advisors's NTLA Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Intellia Therapeutics (NTLA) in Q3 2018, closing a stake of 577 shares — an estimated $16K sold.

Piedmont Investment Advisors first reported a position in NTLA in Q2 2018 and held it in 1 quarter. The position peaked at $16K in Q2 2018. 157 funds tracked by Wall St. Rank hold NTLA as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Intellia Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 577 Intellia Therapeutics shares in Q3 2018, an estimated $16K.
  • Piedmont Investment Advisors first reported a position in Intellia Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Intellia Therapeutics position peaked at $16K in Q2 2018.
  • 157 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.